<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Key opportunities include expanding LAG-3 therapies beyond melanoma, advancing dual and triple checkpoint combinations, developing bispecific antibodies, using biomarkers for patient selection, pursuing label extensions, and forming biotech-pharma partnerships.Dublin, Aug. 20, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/5515332/global-lag-3-targeting-therapy-market-size?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=m7bdvm&amp;utm_campaign=2330600+-+Global+LAG-3+Targeting+Therapy+Market+Outlook+Report+2031%3a+Industry+Size%2c+Approved+Therapy+Dosage%2c+Patent%2c+Sales+%26+Clinical+Trials+Insight&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Global LAG-3 Targeting Therapy Market Size, Approved Therapy Dosage, Patent, Sales &amp; Clinical Trials Insight 2031">"Global LAG-3 Targeting Therapy Market Size, Approved Therapy Dosage, Patent, Sales &amp; Clinical Trials Insight 2031"</a> has been added to ResearchAndMarkets.com's offering. The global LAG-3 targeting therapy market is projected to represent an opportunity of more than USD 5 billion by 2031, supported by commercial validation, expanding immuno-oncology research and the development of new combination therapies. A new market intelligence report provides comprehensive analysis of approved LAG-3 therapies, sales performance, pricing, dosage, patents, clinical trials and the competitive landscape from 2022 through 2031. Report Findings and Highlights <ul><li>Global LAG-3 targeting therapy market opportunity exceeding USD 5 billion by 2031</li><li>Global market size and forecast analysis from 2022 through 2031</li><li>Approved LAG-3 therapy dosage, pricing, patent and sales insights</li><li>Annual and quarterly sales analysis from 2022 through the first quarter of 2026</li><li>Coverage of more than 35 LAG-3 targeting therapies in clinical development</li><li>Clinical trial analysis by company, country, indication and development phase</li><li>Key clinical trial initiation and anticipated completion timelines</li><li>Assessment of leading pharmaceutical and biotechnology companies</li><li>Detailed competitive landscape and future market growth outlook</li></ul> Commercial Development of the LAG-3 Targeting Therapy Market The anti-LAG-3 therapy market has progressed from an experimental segment into a commercially validated immuno-oncology category. Opdualag has established clinical and commercial validation for LAG-3 as an actionable immune checkpoint beyond PD-1 and CTLA-4, providing an important foundation for future immunotherapy combinations. Despite the market's relatively early stage, commercial performance has been strong. Global Opdualag sales exceeded USD 1 billion in 2025, driven by adoption in melanoma treatment and growing physician acceptance of dual checkpoint inhibition. The United States remains the leading revenue-generating market due to early adoption and broad utilization of immuno-oncology therapies. Market concentration remains high, creating substantial opportunities for pharmaceutical companies developing differentiated LAG-3 antibodies, bispecific molecules and multi-checkpoint combinations. Future revenue growth is expected to be supported by additional indications, new treatment settings and potential regulatory approvals for pipeline candidates. LAG-3 Clinical Trials and Pipeline Analysis The report evaluates more than 35 LAG-3 targeting therapies across early-, mid- and late-stage clinical development, including registration-stage studies. It examines clinical progress across melanoma, non-small cell lung cancer, gastric cancer, colorectal cancer, head and neck cancer and other solid tumors. Combination therapy remains the principal strategy in LAG-3 drug development, particularly through the simultaneous inhibition of LAG-3 and PD-1. Fianlimab in combination with cemiplimab is among the late-stage programs being evaluated in melanoma and non-small cell lung cancer. Bispecific drugs designed to target PD-1 and LAG-3 within a single molecule also represent a significant area of clinical research. Additional development strategies include triple-checkpoint combinations involving LAG-3, PD-1 and CTLA-4, as well as regimens incorporating cancer vaccines, oncolytic viruses and other immuno-oncology agents. These approaches are being investigated for their potential to address treatment resistance and improve outcomes among patients who do not achieve durable responses with existing checkpoint inhibitors. Companies Driving LAG-3 Research and Development The competitive landscape includes major pharmaceutical companies and specialized biotechnology organizations. Bristol Myers Squibb, Regeneron and other established immuno-oncology participants are using existing checkpoint inhibitor portfolios to evaluate LAG-3 combinations across multiple cancer indications. Their development priorities include advancing programs beyond Phase II, pursuing label expansions and establishing new first-line treatment options. Biotechnology companies, including Y-Biologics, Immutep and Fontacea Pharmaceutical, are contributing to early-stage innovation through bispecific and multispecific antibody platforms. Selected programs are investigating LAG-3 in combination with other immune pathways, including TIGIT and TIM-3. Licensing agreements, research partnerships and clinical collaborations are expected to remain central to market development. Partnerships between biotechnology innovators and large pharmaceutical companies can provide access to development expertise, global clinical trial infrastructure, manufacturing capacity and commercialization resources. Future Outlook for LAG-3 Targeting Therapies Growth in the global LAG-3 targeting therapy market is expected to extend beyond melanoma as clinical programs advance in lung, colorectal, gastric, head and neck, and other solid tumors. Positive late-stage data could establish LAG-3 inhibitors as components of broader first-line immunotherapy combinations in selected cancer types. Biomarker-guided patient selection may become another important market driver. Clinical development programs are increasingly evaluating defined immune profiles to improve response rates, strengthen therapeutic positioning and support reimbursement decisions. For investors, pharmaceutical companies and biotechnology developers, LAG-3 represents an emerging immunotherapy market with increasing commercial validation and substantial pipeline potential. With approved therapy sales already exceeding USD 1 billion annually in 2025 and more than 35 therapies under clinical investigation, the category is positioned for continued development through 2031. Key Topics Covered: 1. Research Methodology 2. Introduction to LAG-3 Targeting Therapies 2.1 LAG-3 As Therapeutic Target 2.2 LAG-3 Targeting Therapies - Mechanism Of Action 2.3 LAG-3 Targeting Approaches 3. Combination Strategies For LAG-3 Targeting Therapies 4. Global LAG-3 Targeting Therapy Market Scenario 4.1 Current Market Outlook 4.2 Future Market Outlook 5. LAG-3 Targeting Therapy Market Regional Analysis 5.1 US 5.2 EU 5.3 China 5.4 Australia 5.5 UK 5.6 Japan 5.7 Canada 5.8 South Korea 6. Opdualag (Nivolumab &amp; Relatlimab) - Overview, Pricing, Dosing &amp; Sales Analysis 6.1 Overview &amp; Patent Insight 6.2 Pricing &amp; Dosing 6.3 Sales Insight 7. Global LAG-3 Targeting Therapies Clinical Trials Overview 7.1 by Phase 7.2 by Country 7.3 by Company 7.4 by Indication 7.5 by Priority Status 8. Global LAG-3 Targeting Therapies clinical Trials Insight by Company, Country, Indication &amp; Phase 8.1 Research 8.2 Preclinical 8.3 Phase I 8.4 Phase I/II 8.5 Phase II 8.6 Phase II/III 8.7 Phase III 9. Marketed LAG3 Inhibitor Clinical Insight 10. LAG-3 Targeting Therapy - Development Trends by Indication 10.1 Cancer 10.1.1 Hematological Malignancies 10.1.2 Solid Tumors 10.2 Autoimmune &amp; Inflammatory Diseases 10.3 Microbial Infections 11. Global LAG-3 Targeting Therapy Market Dynamics 11.1 Market Drivers 11.2 Market Challenges 12. Competitive Landscape 12.1 ABL Bio 12.2 Agenus 12.3 Akeso Biopharma 12.4 Bristol-Myers Squibb 12.5 EpimAb Biotherapeutics 12.6 Immutep 12.7 Innovent Biologics 12.8 Regeneron 12.9 Shanghai Henlius Biotech 12.10 Y-Biologics List of Figures Figure 2-1: LAG-3/MHC Class II Signaling Pathway Figure 2-2: LAG-3 Targeted Therapy Landscape - Milestones Figure 2-3: LAG-3 Inhibitor - Mechanism Of Action Figure 2-4: LAG-3 Agonist - Mechanism Of Action Figure 2-5: LAG-3 Depletion - Mechanism Of Action Figure 2-6: Bispecific Antibodies - Binding Efficacy Figure 3 1: Possible LAG-3 Combinations Figure 4-1: Global - LAG 3 Targeting Therapy Market (US$ Million), 2022-2026 Figure 4-2: Global - LAG 3 Targeting Therapy Market by Region (US$ Million), Q1'2026 Figure 4-3: Global - LAG 3 Targeting Therapy Market by Region (US$ Million), 2025 Figure 4-4: Global - Quarterly LAG 3 Targeting Therapy Market (US$ Million), 2025 Figure 4-5: Global - LAG 3 Targeting Therapy Market by Region (%), 2024 Figure 4-6: Global - LAG 3 Targeting Therapy Market Forecast (US$ Million), 2026-2031 Figure 4-7: Global LAG-3 Targeting Therapy Market - Future Outlook Figure 5-1: EU - Research Institutes &amp; Hospitals Conducting LAG-3 Therapy Clinical Trials Figure 6-1: Opdualag - Approval Year by Region Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year by Region Figure 6-3: US - Cost Per Unit &amp; Supply Of Opdualag (US$), May'2026 Figure 6-4: UK - Cost Per Unit &amp; Supply Of Opdualag (US$), May'2026 Figure 6-5: Global - Opdualag Annual Sales (US$ Million), 2022-2026 Figure 6-6: Global - Opdualag Annual Sales by Region (US$ Million), Q1'2026 Figure 6-7: Global - Opdualag Quarterly Sales (US$ Million), 2025 Figure 6-8: US - Opdualag Annual Sales (US$ Million), 2024-2026 Figure 6-9: US - Opdualag Quarterly Sales (US$ Million), 2025 Figure 6-10: ROW - Opdualag Sales (US$ Million), 2024-2026 Figure 6-11: ROW - Opdualag Quarterly Sales (US$ Million), 2025 Figure 6-12: Opdualag - US v/s ROW Sales (US$ Million), 2024 Figure 6-13: Global - Opdualag Sales (US$ Million), 2024 Figure 6-14: US - Opdualag Sales (US$ Million), 2022-2024 Figure 6-15: US - Opdualag Sales (US$ Million), Q1-Q4'2024 Figure 6-16: ROW - Opdualag Sales (US$ Million), 2022-2024 Figure 6-17: ROW - Opdualag Sales (US$ Million), Q1-Q4'2024 Figure 7-1: Global - LAG-3 Inhibitor Clinical Trials by Phase (Numbers), 2026-2031 Figure 7-2: Global - LAG-3 Inhibitor Clinical Trials by Country (Numbers), 2026-2031 Figure 7-3: Global - LAG-3 Inhibitor Clinical Trials by Company (Numbers), 2026-2031 Figure 7-4: Global - LAG-3 Inhibitor Clinical Trials by Indication (Numbers), 2026-2031 Figure 7-5: Global - LAG-3 Inhibitor Clinical Trials by Priority Status (Numbers), 2026-2031 Figure 10-1: RELATIVITY-047 Phase 2/3 (NCT03470922) Study - Initiation &amp; Completion Year Figure 10-2: AK129-102 Phase 1/2 (NCT06642792) Study - Initiation &amp; Completion Year Figure 10-3: AK129-102 Phase 1/2 (NCT05137054) Study - Initiation &amp; Completion Year Figure 10-4: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study - Initiation &amp; Completion Year Figure 10-5: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study - Initiation &amp; Completion Year Figure 10-6: R2810-ONC-1866 Phase 2 (NCT03916627) Study - Initiation &amp; Completion Year Figure 10-7: R2810-ONC-2266 Phase 2 (NCT06161441) Study - Initiation &amp; Completion Year Figure 10-8: J23155 Phase 2 (NCT06205836) Study - Initiation &amp; Completion Year Figure 10-9: RELATIVITY-104 Phase 2 (NCT04623775) Study - Initiation &amp; Completion Year Figure 10-10: RELATIVITY-1093 Phase 3 (NCT06561386) Study - Initiation &amp; Completion Year Figure 10-11: J1714 Phase 1b (NCT03044613) Study - Initiation &amp; Completion Year Figure 10-12: HCC 18-139 Phase 2 (NCT04080804) Study - Initiation &amp; Completion Year Figure 10-13: CA209-1451 Phase 2 (NCT06624475) Study - Initiation &amp; Completion Year Figure 10-14: MIA2023/490 Phase 2 (NCT06288191) Study - Initiation &amp; Completion Year Figure 10-15: MIA2023/489 Phase 2 (NCT06151236) Study - Initiation &amp; Completion Year Figure 10-16: IMP761-P001 Phase 1 (NCT06637865) Study - Initiation &amp; Completion Year Figure 11-1: Global LAG-3 Targeting Therapy Market - Drivers &amp; Opportunities Figure 11-2: Global LAG-3 Targeting Therapy Market - Challenges &amp; Restraints List of Tables Table 3-1: Ongoing Preclinical &amp; Clinical Trials For Combination of LAG-3 inhibitors Table 5-1: Immutep - Active Patents by Region Table 6-1: Opdualag - Maximum Infusion Volumes &amp; Concentration Ranges by Patient Group Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions A selection of companies mentioned in this report includes, but is not limited to: <ul><li>ABL Bio</li><li>Agenus</li><li>Akeso Biopharma</li><li>Bristol-Myers Squibb</li><li>EpimAb Biotherapeutics</li><li>Immutep</li><li>Innovent Biologics</li><li>Regeneron</li><li>Shanghai Henlius Biotech</li><li>Y-Biologics</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5515332/global-lag-3-targeting-therapy-market-size?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=m7bdvm&amp;utm_campaign=2330600+-+Global+LAG-3+Targeting+Therapy+Market+Outlook+Report+2031%3a+Industry+Size%2c+Approved+Therapy+Dosage%2c+Patent%2c+Sales+%26+Clinical+Trials+Insight&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/jz5yex</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YjhmMWMwODgtYjVjNS00ZmYzLTgyMWUtZTY1ZGI1ZTFlOGZlLTEwMjY3MzctMjAyNi0wOC0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global LAG-3 Targeting Therapy Market Outlook Report 2031: Industry Size, Approved Therapy Dosage, Patent, Sales & Clinical Trials Insight

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn